Evidence map›Paper›PMID 33245531›Full record

ArticleAdvances in therapy2021

A Patient Charter for Chronic Obstructive Pulmonary Disease.

John R Hurst, Tonya Winders, Heinrich Worth, Mohit Bhutani, Kevin Gruffydd-Jones, Daiana Stolz, Mark T Dransfield

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Severe COPD: Multidisciplinary Consultation to Get the Right Care at the Right Place.International journal of chronic obstructive pulmonary disease · 2024
    Article
  6. Observational
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

John R HurstUCL Respiratory, University College London, London, UK. j.hurst@ucl.ac.uk.
Tonya WindersAllergy and Asthma Network, Global Allergy and Airways Patient Platform, Vienna, VA, USA.
Heinrich WorthVice-Chairman of the German Airways League, Specialists Forum, Furth, Germany.
Mohit BhutaniDivision of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Kevin Gruffydd-JonesBox Surgery, Box, Corsham, Wiltshire, UK.
Daiana StolzClinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.
Mark T DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, The University of Alabama at Birmingham, Birmingham, AL, USA.
University College London · GBUniversity Hospital of Basel · CHUniversity of Alabama at Birmingham · USUniversity of Alberta · CAWiltshire College · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) has a profound impact on people living with the disease and has a high global economic and social burden. Often, people with COPD are undiagnosed, while those diagnosed are undertreated and undereducated on different aspects of COPD care. Although there are many published evidence-based treatment guidelines from different expert groups and societies, they are frequently not adhered to, which results in significant gaps in care. In particular, 'flare-ups' (known as exacerbations of COPD), which accelerate disease progression, are often under-reported, despite guidelines recommending an escalation of maintenance treatment to prevent subsequent flare-ups. Management of COPD should be proactive to prevent worsening of symptoms and to reduce the risk of future flare-ups and premature death, rather than a secondary reaction to a worsening health status. Key to this is patient access to accurate diagnosis, effective treatment and specialist care, which can vary widely due to socioeconomic differences, geographical locations and poor guideline implementation. In addition, the stigma associated with COPD can act as a barrier, which can result in people being reluctant to access treatment or clinicians being nihilistic. As global patient advocates, we have co-developed this patient charter to set a standard of care that people living with COPD should expect, raising awareness and understanding of the causes and consequences of COPD as well as the potential to improve patient care. Patients with COPD should be empowered to live the highest quality of life possible with the least number of flare-ups. We set out six principles in line with current COPD guideline recommendations, that should be implemented by governments, healthcare providers, policymakers, lung health industry partners and patients/caregivers to drive meaningful change in COPD care.

Indexed as

Pulmonary Disease, Chronic ObstructiveQuality of LifeCaregiversDisease ProgressionHumansPatient CareCaregiversChronic obstructive pulmonary diseasePatient advocacyPatient careQuality of lifeSocioeconomic factorsTreatment outcome

Identifiers

PMID33245531
PMCPMC7854443
OpenAlexW3109214388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.